NOXXON begins collaboration with the US National Cancer Institute to characterize the effects of lead compounds on brain tumors


Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.

BERLIN–(BUSINESS WIRE)–Regulatory news:

NOXXON Pharma AG (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today it has entered into a material transfer agreement with the US National Cancer Institute (NCI), National Institutes of Health (NIH), to further explore the effects of NOXXON’s lead compounds, the CXCL12 inhibitor NOX -A12 and the CCL2 inhibitor NOX-E36, individually and in combination, on brain tumors.

The research program will be led by Marc R. Gilbert, MD, chief of the neuro-oncology branch at the National Cancer Institute Cancer Research Center (NCI/CCR), which is part of the NIH. Under this agreement, NOXXON will provide NOX-A12 and mNOX-E361 to the NCI, which will perform preclinical testing in various combinations with immunomodulatory treatments, including immune checkpoint inhibitors. The different combinations will be tested in a series of experiments in three mouse models of brain cancer, with in-depth and detailed characterization of the tumor microenvironment.

“We are proud and excited to partner with NCI to further our understanding of our lead compounds, NOX-A12 and NOX-E36, in brain tumors. By using three different models of brain cancer with distinct immunological characteristics, this research will greatly improve the understanding of the effect of our compounds on tumor biology. The work should also provide insight into whether and how our CXCL12 and CCL2 antagonist can be synergistic with other approaches to alter the brain tumor microenvironment, with the aim of facilitating a relevant anti-tumor immune response.” , said Aram Mangasarian, CEO of NOXXON.

NOX-A12 is being studied in the Phase 1/2 GLORIA dose-escalation study in patients with brain cancer (glioblastoma), front line data which were presented at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held in Chicago, Illinois, USA, on June 5, 2022. The NCI is not participating in this clinical study.


NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and cancer immunity cycle by breaking down the tumor protective barrier and blocking tumor repair. By neutralizing chemokines in the TME, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON’s lead program, NOX-A12, provided final data from a combined Keytruda® trial in patients with metastatic colorectal and pancreatic cancer, released at the ESMO conference in September 2020 and in July 2021 the company announced. announced its Phase 2 study, OPTIMUS, to further assess the safety and efficacy of NOX-A12 in combination with Merck’s Keytruda® and two different chemotherapy regimens as a second-line treatment in cancer patients metastatic pancreas. NOXXON is also studying NOX-A12 in brain cancer in combination with radiation therapy, which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. GLORIA, a trial of NOX-A12 in combination with radiation therapy in newly diagnosed brain cancer patients who will not clinically benefit from standard chemotherapy, provided frontline data from all three climbing cohorts of dose showing consistent tumor reductions and objective tumor responses. Additionally, GLORIA was expanded to assess the benefit of NOX-A12 with other treatment combinations, radiotherapy + bevacizumab and radiotherapy + pembrolizumab. The Company’s second clinical-stage asset, NOX-E36, is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors. Further information can be found at:

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.

Visit NOXXON at LinkedIn and Twitter.

About the GLORIA study

GLORIA (NCT04121455) is NOXXON’s dose-escalating Phase 1/2 study of NOX-A12 in combination with radiation in first-line patients with partially resected or unresected glioblastoma (brain cancer) with a promoter Unmethylated MGMT (resistant to standard chemotherapy). GLORIA is further evaluating the safety and efficacy of NOX-A12 in three additional arms combining NOX-A12 with: A. radiation therapy in patients with complete tumor resection; B. radiotherapy and bevacizumab; and C. radiation therapy and pembrolizumab.

About the OPTIMUS study

OPTIMUS (NCT04901741) is NOXXON’s open-label, two-arm Phase 2 study of NOX-A12 plus pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in patients with stable microsatellite metastatic pancreatic cancer.


Translations of any press release into languages ​​other than English are for the convenience of non-English speaking audiences only. The company has attempted to provide an accurate translation of the original English text, but due to nuances of translating into another language, slight differences may exist. Certain statements in this communication contain formulations or terms that refer to future or future developments, as well as negations of these formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information contained in this communication regarding expected or future results of business segments, financial indicators, changes in financial condition or other financial or statistical data contains such forward-looking statements. The company cautions potential investors not to rely on these forward-looking statements as certain predictions of actual future events and developments. The company is neither responsible nor liable for updating this information, which only represents the current situation on the day of publication.

1 NOX-E36 not being active in rodents; the Spiegelmer mNOX-E36 surrogate that binds and inactivates mouse and rat CCL2 will be used for these experiments.

For more information please contact:


Aram Mangasarian, Ph.D.

Chief executive officer

Such. +49 (0) 30 726247 0

[email protected]

Investor and Media Relations:

LifeSci Advisors

Guillaume van Renterghem

Such. +41 (0) 76 735 01 31

[email protected]


Arthur Rusty

Such. +33 (0)1 44 71 00 15

[email protected]

Source: NOXXON Pharma SA


Comments are closed.